COVID-19 outcomes among patients with sickle cell disease or sickle cell trait compared to the general population: a systematic review and meta-analyses

IF 3 3区医学 Q2 HEMATOLOGY

Annals of Hematology Pub Date : 2024-12-11 DOI:10.1007/s00277-024-06113-z

Yachar Dawudi, Loris Azoyan, Matthieu Bonjour, Olivier Steichen

{"title":"COVID-19 outcomes among patients with sickle cell disease or sickle cell trait compared to the general population: a systematic review and meta-analyses","authors":"Yachar Dawudi, Loris Azoyan, Matthieu Bonjour, Olivier Steichen","doi":"10.1007/s00277-024-06113-z","DOIUrl":null,"url":null,"abstract":"<div><p>Individuals with sickle cell disease (SCD) and sickle cell trait (SCT) face an increased risk of complications from COVID-19 due to their susceptibility to infections and venous thromboembolism. We selected 28 studies from 3228 references in bibliographic databases to compare COVID-19 outcomes (hospitalization, ICU admission, need for ventilatory support, thromboembolic events, and mortality) between patients with SCD or SCT and control patients. Compared to control patients, the pooled risk of hospitalization was not significantly higher in those with SCT (odds ratio [OR] 1.13, 95% confidence interval [CI] 0.94–1.34) but the pooled risk of death was higher (OR 1.43, 95% CI 1.14–1.78). Compared to controls patients, those with SCD had a much higher pooled risk of hospitalization (OR 7.79, 95% CI 5.13–11.81) and a non-different risk of death once hospitalized (OR 0.82, 95% CI 0.62–1.10), resulting in an overall increased risk of death (OR 1.94, 95% CI 1.26–2.98).</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"103 12","pages":"5071 - 5083"},"PeriodicalIF":3.0000,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s00277-024-06113-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Individuals with sickle cell disease (SCD) and sickle cell trait (SCT) face an increased risk of complications from COVID-19 due to their susceptibility to infections and venous thromboembolism. We selected 28 studies from 3228 references in bibliographic databases to compare COVID-19 outcomes (hospitalization, ICU admission, need for ventilatory support, thromboembolic events, and mortality) between patients with SCD or SCT and control patients. Compared to control patients, the pooled risk of hospitalization was not significantly higher in those with SCT (odds ratio [OR] 1.13, 95% confidence interval [CI] 0.94–1.34) but the pooled risk of death was higher (OR 1.43, 95% CI 1.14–1.78). Compared to controls patients, those with SCD had a much higher pooled risk of hospitalization (OR 7.79, 95% CI 5.13–11.81) and a non-different risk of death once hospitalized (OR 0.82, 95% CI 0.62–1.10), resulting in an overall increased risk of death (OR 1.94, 95% CI 1.26–2.98).

查看原文本刊更多论文

镰状细胞病患者或镰状细胞特征患者的COVID-19结局与一般人群的比较：系统综述和荟萃分析

镰状细胞病（SCD）和镰状细胞特征（SCT）患者因易感染和静脉血栓栓塞而面临COVID-19并发症的风险增加。我们从文献数据库中的3228篇文献中选择了28篇研究，比较SCD或SCT患者与对照患者的COVID-19结局（住院、ICU住院、呼吸支持需求、血栓栓塞事件和死亡率）。与对照患者相比，SCT患者住院的综合风险没有显著增加（优势比[OR] 1.13, 95%可信区间[CI] 0.94-1.34），但死亡的综合风险更高（OR 1.43, 95% CI 1.14-1.78）。与对照患者相比，SCD患者住院总风险更高（OR 7.79, 95% CI 5.13-11.81），住院后死亡风险无差异（OR 0.82, 95% CI 0.62-1.10），导致总体死亡风险增加（OR 1.94, 95% CI 1.26-2.98）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Hematology 医学-血液学

CiteScore

5.60

自引率

2.90%

发文量

304

审稿时长

2 months

期刊介绍： Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.